Ra Medical Systems was founded in 2002 to design, develop, and commercialize excimer lasers as tools for the treatment of vascular and dermatological diseases. The Company was incorporated in California on September 4, 2002 and reincorporated in Delaware in July 2018.
Pharos excimer laser system was launched in October 2004 and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma.
In May 2017, DABRA laser system and disposable DABRA catheter received FDA 510(k) clearance in the U.S. for the intended use of ablating a channel in occlusive peripheral vascular disease.
DABRA and Pharos are both based on our core excimer laser technology platform and deploy similar mechanisms of action. Independent in vivo and in vitro research studies have demonstrated that 308 nanometer excimer laser light, which is the same wavelength used in DABRA and Pharos, increases T-cell apoptosis, or cell death, which may produce an immunosuppressive effect.
We manufacture our DABRA and Pharos excimer lasers and catheters in our approximately 32,000-square-foot facility located in Carlsbad, California. Our vertically integrated facility is ISO 13485 certified and is licensed by the state of California to manufacture our sterile, single-use catheters in our controlled environments.
Keep Up To Date On Our Advancements
In addition to advancing excimer laser medicine, Ra Medical Systems is committed to keeping physicians, patients, and shareholders up-to-date on the latest news surrounding the growth of our company and industry. Our Newsroom features a resourceful compendium of press releases, videos, interviews, and the latest news about our excimer lasers.
Looking Back on a Decade of Innovation
In 2006, Fox News ran this story on Ra Medical Systems. Our company was only 4 years old then and already making waves as industry leaders. The same innovation that led the way a decade ago still drives us to constantly improve our revolutionary technology.
New Study Shows DABRA Laser System Achieved 94% Success Rate in Patients with Peripheral Artery Disease
March 07, 2019 CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE: RMED), today announced study results from Athar Ansari, MD, Director of the California Heart & Vascular Clinic, who stated, “DABRA is fundamentally changing the way I practice medicine.” Dr. Ansari’s study demonstrated a 94% success... Read More
The Growing Role of Lasers in Treatments for Better Blood Flow
Thanks to evolving technologies, treatments for diseases of the heart, arteries, and veins could soon see improvements by way of the laser. HANK HOGAN, CONTRIBUTING EDITOR For some cardiovascular patients, laser-based procedures have become the best, and perhaps only, option to relieve pain and restore function... Read More
New Data Presented at LINC 2019 Demonstrates Acute Success with DABRA Excimer Laser System for the Treatment of Peripheral Artery Disease
Study achieved a statistically significant difference in pre- and post-percent stenosis and ABI values CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE: RMED), a leading developer and manufacturer of commercial excimer laser systems to treat vascular and dermatological diseases, today announced a 98% success rate in... Read More
Ra Medical Systems Appoints Thomas Fogarty as Chief Commercial Officer
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) hires Thomas Fogarty as Chief Commercial Officer, effectively immediately. Mr. Fogarty brings over two decades of medical device leadership and commercialization experience to Ra Medical Systems and will oversee all aspects of the Company's commercialization efforts, which include the sales... Read More